Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism [0.03%]
AMXT 1501二棕榈酸酯联合二氟甲基鸟氨酸Ⅰ期剂量递增试验:靶向免疫抑制型聚胺代谢的双重策略
S A Piha-Paul,A W Tolcher,A L Vandross et al.
S A Piha-Paul et al.
Background: Dysregulation of polyamine synthesis has been observed in various cancer cell types. A novel approach to depriving cancer cells of polyamines involves the use of difluoromethylornithine (DFMO) to block polyami...
Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge [0.03%]
HR阳性/HER2阴性早期乳腺癌在辅助使用CDK4/6抑制剂期间或之后发生复发的管理:一个新兴挑战
R Gerosa,G Gentile,L Arecco et al.
R Gerosa et al.
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), such as abemaciclib and ribociclib, have recently been incorporated as adjuvant strategy in combination with endocrine therapy (ET) for patients with hormone receptor-positive, human epi...
HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy [0.03%]
曲妥珠单抗联合化疗治疗晚期HER2阳性胃癌的HER2DX ERBB2评分
D Pesántez,F Brasó-Maristany,T Pascual et al.
D Pesántez et al.
Background: Response to trastuzumab combined with chemotherapy (T-chemo) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) varies widely, highlighting the need for more precise biom...
Toxicity and efficacy of antibody-drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trials [0.03%]
抗体偶联药物治疗晚期实体瘤的疗效与毒性:临床试验的回顾性分析
R Woodford,H Almarzouq,N Beygozlu et al.
R Woodford et al.
Background: Antibody-drug conjugates (ADCs) combine targeted monoclonal antibodies with cytotoxic payloads and are an emerging modality in systemic cancer therapy. Thirteen ADCs are Food and Drug Administration approved, ...
Induction immunotherapy plus chemotherapy for Pancoast lung cancer tumors: are we ready to shift our standards? [0.03%]
诱导免疫疗法联合化疗治疗肺尖肿瘤:我们准备好改变标准了吗?
J Remon,F Porez,H Clermidy et al.
J Remon et al.
Pancoast tumors are a distinct and rare subset of non-small-cell lung cancers (NSCLCs). Although a trimodality approach combining induction chemoradiotherapy followed by surgery has been the standard of care over the past two decades, only ...
Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study [0.03%]
J-ALEX研究中血浆cfDNA对alectinib耐药相关基因改变的分析
H Sakaguchi,R Katayama,M Matsumoto et al.
H Sakaguchi et al.
Background: Resistance to alectinib, the standard first-line therapy for anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), remains a major clinical challenge. This study aimed to investigate ...
Impact of rare EGFR exon 19 insertion-deletion variants on tyrosine kinase inhibitor efficacy in non-small-cell lung cancer: a 5-year multicenter analysis [0.03%]
罕见EGFR 19外显子插入缺失变异型对非小细胞肺癌酪氨酸激酶抑制剂疗效的影响:一项为期五年的多中心研究分析
J Xu,W Zhang,F Cheng et al.
J Xu et al.
Background: The clinical impact of rare epidermal growth factor receptor (EGFR) exon 19 insertion-deletion (19delins) variants on tyrosine kinase inhibitor (TKI) efficacy remains poorly characterized. We updated 5-year ou...
Consensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in China [0.03%]
中国鼻咽癌多学科免疫治疗共识陈述
G Wang,J Qin,W Nong et al.
G Wang et al.
Introduction: This study aims to establish a multidisciplinary consensus on the treatment of nasopharyngeal carcinoma (NPC) in China, with a particular focus on the guidelines for the use of immune checkpoint inhibitors (...
F André,E Rassy,B Achutti-Duso et al.
F André et al.
Explainable machine learning models based on clinical trial surrogate outcomes for predicting overall survival in head and neck cancers [0.03%]
基于临床试验替代结果的可解释机器学习模型,用于预测头颈部癌症的整体生存率
W Hwang,H A Jung,L J Worth et al.
W Hwang et al.
Background: This study aimed to evaluate the relationship between surrogate efficacy outcomes and overall survival (OS) in clinical trials for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), and...